Project description

Resistant hypertension is estimated to affect approximately 25% of hypertensive patients on treatment. Screening for a secondary cause such as primary aldosteronism is strongly indicated. However, are patients actually being screened in primary care? If we systematically test for primary aldosteronism in this population, what proportion will be found to have the condition? We will work with research-focussed primary care clinics and general practitioners to co-design a strategy to screen these patients for a potentially curable cause of hypertension.